Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 4:55 PM ET


Company Overview of Xencor, Inc.

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical t...

111 West Lemon Avenue

Monrovia, CA 91016

United States

Founded in 1997

37 Employees





Key Executives for Xencor, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 45
Total Annual Compensation: $400.0K
Chief Medical Officer
Age: 61
Total Annual Compensation: $369.0K
Chief Business Officer
Age: 56
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice President of Research
Age: 51
Total Annual Compensation: $289.3K
Compensation as of Fiscal Year 2014.

Xencor, Inc. Key Developments

Xencor, Inc. - Analyst/Investor Day

To provide updates on its XmAb5871 and XmAb7195 development programs and its XmAb14045 and XmAb bispecific pipeline

Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

Xencor, Inc. reported complete data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA). XmAb5871 was generally well tolerated and showed trends in improvement in RA disease activity by multiple disease activity measures and across multiple dose groups. The two-part study was designed as a Phase 1b multiple center, randomized, placebo-controlled, double-blinded, multiple ascending dose clinical study (Part A) followed by Phase 2a cohort extension (Part B) at the top dose examined in Part A. The study enrolled patients with active RA on stable non-biologic DMARD therapy. Patients were randomized to receive ascending IV infusions of XmAb5871 (0.3, 1.0, 3.0 and 10.0 mg/kg) or placebo 14 days apart for six doses (Part A), followed by an expansion cohort at 10.0 mg/kg or placebo 14 days apart for six doses (Part B). XmAb5871 was safe and generally well tolerated. The most common AEs in the XmAb5871 group were vomiting, headache and nausea. Nausea and vomiting occurred primarily during the first infusion, were generally of mild to moderate intensity and were self-limiting. Two subjects in the study experienced infusion-related reactions with hypotension (both at 10 mg/kg) and were discontinued. The nature and severity of these infusion reactions were consistent with those reported for other monoclonal antibody therapies. Two SAEs occurred in two XmAb5871 treated patients, both in the 10 mg/kg group: one infusion-related reaction with hypotension occurring during the second infusion, and one deep venous thrombosis with onset 22 days (> 6 half-lives) after the last infusion.

Xencor, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:30 AM

Xencor, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Cellular Research, Inc. United States
Sirna Therapeutics, Inc. United States
PML Microbiologicals, Inc. United States
Tolero Pharmaceuticals, Inc. United States
Calibrium, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Xencor, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at